<

SANOFI-AVENTIS (EPA:SAN) FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50%

Transparency directive : regulatory news

22/02/2021 19:00



Other stories

26/04/2024 12:40
26/04/2024 11:23
26/04/2024 11:42
26/04/2024 11:56
26/04/2024 12:04
26/04/2024 05:00
26/04/2024 10:13
26/04/2024 10:54
26/04/2024 09:20
26/04/2024 12:34
26/04/2024 09:40
26/04/2024 00:39
26/04/2024 00:20
26/04/2024 01:32
26/04/2024 10:31
26/04/2024 11:26
26/04/2024 10:24
25/04/2024 23:05
26/04/2024 11:50
25/04/2024 08:39
25/04/2024 18:17
26/04/2024 11:59
26/04/2024 12:52
26/04/2024 01:01
26/04/2024 11:31
25/04/2024 19:34
26/04/2024 09:51
26/04/2024 11:56
26/04/2024 09:56
26/04/2024 11:10
25/04/2024 19:30
26/04/2024 10:24
25/04/2024 13:28
25/04/2024 21:00
26/04/2024 09:18
26/04/2024 11:14
26/04/2024 03:31
25/04/2024 14:56